After Moderna's experimental COVID-19 vaccine produced protective antibodies in a small group of volunteers, its CEO Stéphane Bancel said that data "couldn't have been better". "This is a very good sign that we make an antibody that can stop the virus from replicating," Bancel said. The data comes from first eight people who each received two doses of the vaccine.